Literature DB >> 11806717

Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics.

Bangwei Ding1, Qunying Guan, Joshua P Walsh, J Scott Boswell, Tim W Winter, Erica S Winter, Stephanie S Boyd, Chunhong Li, Paul B Savage.   

Abstract

The antibacterial activities of cationic steroid antibiotics and cationic peptide antibiotics have been compared. Depolarization of bacterial membranes, activation of bacterial stress-related gene promoters, and changes in bacterial morphologies caused by these antibiotics suggest that cationic steroid and peptide antibiotics share mechanistic aspects. Modified cationic steroid antibiotics display improved selectivity for prokaryotic cells over eukaryotic cells presumably due to increased charge recognition.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11806717     DOI： 10.1021/jm0105070

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  31 in total

1.  Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.

Authors:  Urszula Wnorowska; Katarzyna Niemirowicz; Melissa Myint; Scott L Diamond; Marta Wróblewska; Paul B Savage; Paul A Janmey; Robert Bucki
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Role of the HefC efflux pump in Helicobacter pylori cholesterol-dependent resistance to ceragenins and bile salts.

Authors:  Elizabeth A Trainor; Katherine E Horton; Paul B Savage; Traci L Testerman; David J McGee
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

3.  Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus.

Authors:  Judy N Chin; Michael J Rybak; Chrissy M Cheung; Paul B Savage
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

4.  Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins.

Authors:  Raquel F Epand; Jake E Pollard; Jonathan O Wright; Paul B Savage; Richard M Epand
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

5.  In vitro evaluation of the potential for resistance development to ceragenin CSA-13.

Authors:  Jake E Pollard; Jason Snarr; Vinod Chaudhary; Jacob D Jennings; Hannah Shaw; Bobbie Christiansen; Jonathan Wright; Wenyi Jia; Russell E Bishop; Paul B Savage
Journal:  J Antimicrob Chemother       Date:  2012-08-16       Impact factor: 5.790

6.  Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.

Authors:  Robert Bucki; Dorota B Namiot; Zbigniew Namiot; Paul B Savage; Paul A Janmey
Journal:  J Antimicrob Chemother       Date:  2008-05-01       Impact factor: 5.790

7.  Minimum requirements of hydrophobic and hydrophilic features in cationic peptide antibiotics (CPAs): pharmacophore generation and validation with cationic steroid antibiotics (CSAs).

Authors:  Sandeep Sundriyal; Rohit K Sharma; Rahul Jain; Prasad V Bharatam
Journal:  J Mol Model       Date:  2008-02-13       Impact factor: 1.810

8.  Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines.

Authors:  Rajalakshmi Balakrishna; Stewart J Wood; Thuan B Nguyen; Kelly A Miller; E V K Suresh Kumar; Apurba Datta; Sunil A David
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Antimicrobial activity of the iron-sulfur nitroso compound Roussin's black salt [Fe4S3(NO)7] on the hyperthermophilic archaeon Pyrococcus furiosus.

Authors:  Scott D Hamilton-Brehm; Gerrit J Schut; Michael W W Adams
Journal:  Appl Environ Microbiol       Date:  2009-02-05       Impact factor: 4.792

10.  Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.

Authors:  Katarzyna Leszczyńska; Andrzej Namiot; David E Fein; Qi Wen; Zbigniew Namiot; Paul B Savage; Scott Diamond; Paul A Janmey; Robert Bucki
Journal:  BMC Microbiol       Date:  2009-09-03       Impact factor: 3.605
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.